Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-05-28
DOI
https://doi.org/10.1200/jco.2025.43.16_suppl.4507
Citations
2
Primary Topic
Cancer, Hypoxia, and Metabolism
Type
article
Field-Weighted Citation Impact
1.87
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.

Tobias Else, Eric Jonasch, Benjamin Louis Maughan, Ramaprasad Srinivasan et al.
2 citations
Journal of Clinical Oncology
Cancer, Hypoxia, and Metabolism
1.87
article

Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.

Tobias Else, Eric Jonasch, Benjamin Louis Maughan, Ramaprasad Srinivasan, Jodi K. Maranchie, Othon Iliopoulos, Ane Bundsbæk Bøndergaard Iversen, Jerry Cornell, Stéphane Oudard, Vivek Narayan, Rodolfo F. Perini, Yanfang Liu, W. Marston Linehan, Katy Beckermann
article en
2 citations

Abstract

No abstract available for this paper.
Journal of Clinical OncologyVol. 43(16_suppl)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), National Institutes of Health (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Vanderbilt University (US), Université Paris Cité (FR), University of Utah (US), University of Michigan (US), Hospital of the University of Pennsylvania (US), Huntsman Cancer Institute (US), Aarhus University Hospital (DK), Massachusetts General Hospital (US), Assistance Publique – Hôpitaux de Paris (FR), Hôpital Européen Georges-Pompidou (FR), University of Pittsburgh Medical Center (US), National Cancer Institute (US)
Openalex Percentile: Top 14%
Cancer, Hypoxia, and Metabolism
1.87
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study. — Tobias Else, Eric Jonasch, et al. · Journal of Clinical Oncology (2025) | TGRS Research Map | TGRS